FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283707581> ?p ?o ?g. }

• W4283707581 endingPage "1068" @default.
• W4283707581 startingPage "1068" @default.
• W4283707581 abstract "Background Rheumatic diseases prevalence and characteristics in Mexico may vary depending on the country´s region 1 . To acknowledge these differences is needed to develop focused strategies for early diagnosis and treatment 2 . Objectives Identify the sociodemographic, clinical and treatment characteristics of the rheumatic diseases in the different regions in Mexico using data from the Mexican Adverse Events Registry (BIOBADAMEX). Methods In this analysis we included all patients registered from 2016 to 2021. We described the prevalence in the northern region of Mexico (NR), central (CR) and southern region (SR). We compared sociodemographic, clinical and treatment characteristics between these three regions. We used descriptive statistics, Chi square and Kruskal Wallis tests to analyze differences between the groups. Results A total of 780 patients were included in this study, 248 patients (32%) were from the NR, 471 (60%) were from the CR and 61 (8%) from the SR. At baseline, patients had a median (IQR) age of 50 (40-58) years and median disease duration of 7 (3-15) years. NR patients had longer disease duration (9.7 years, p <0.001) and SR patients had higher BMI (29, p 0.001). Overall, 351 (45%) had comorbidities. In CR and SR more than the half of the patient had comorbidities, while in NR only 29% (p 0.001). The most common diagnosis was rheumatoid arthritis with 512 (66%) patients, followed by ankylosing spondylitis in 115 (15%), psoriatic arthritis in 44 (6%), systemic lupus erythematosus in 30 (4%) and idiopathic juvenile arthritis in 27 (3%), this proportions were maintained when analyzed by regions. We found SR had higher DAS 28 and higher BASDAI (Table 1). Table 1. Baseline characteristics by region. Northern regionn=248 Central regionn=471 Southern regionn=61 p Age, median(IQR) 49.7 (42-58) 49.9 (38-58) 51.6 (43-61) 0.4 Female, n(%) 193 (78) 383 (81) 52 (85) 0.33 Body Mass Index, median (IQR) 28 (25-32) 26 (22-29) 29 (26-32 ) 0.001 Disease duration (years), median (RIC) 9.7 (5-16 ) 5.9 (2-14) 4.5 (1-10) 0.001 Diagnostic, n(%): Rheumatoid arthritis 173 (70 ) 300 (64) 39 (64) 0.001 Idiopathic Juvenile Arthritis 3 (1) 23 (5 ) 1 (2) Ankylosing Spondylitis 47 (19 ) 59 (13) 9 (15) Laboratory studies, n(% ) Rheumatoid factor 97 (39) 274 (58) 38 (62 ) 0.001 ACPA 15 (6) 68 (14) 12 (19 ) 0.001 Disease activity scores, median (IQR ) DAS28 4.8 (3-6) 5.1 (4-6) 5.2 (5-7 ) 0.001 BASDAI 2.8 (0-7) 4.9 (2-7) 8.0 (5-9 ) 0.003 Comorbidities, n(% ) 72 (29) 247 (52 ) 32 (52 ) 0.001 Previous bDMARD, n(%): 136 (55 ) 149 (32) 1 (2) 0.001 Steroids, n(%): 93 (38) 155 (33) 42 (69 ) 0.001 cDMARD, n(% ) 200 (81) 373 (79) 53 (87) 0.4 Cause of bDMARD discontinuation, n(% ) a Lack of efficacy 85 (62 ) 45 (33) 2 (22) 0.001 Adverse Event 4 (3) 25 (18) 3 (33 ) Pregnancy 1 (1) 3 (2 ) 0(0) Loss of patient follow up 10 (7) 0 (0) 2 (22 ) Remission 23 (17 ) 5 (4) 0 (0) Others 14 (10) 59 (43 ) 2(22) a) 238 patients. Glucocorticoids were used by 290 (37%) patients, SR had the highest use rate (69%, p <0.001) and 80% of the patients used conventional DMARDs (cDMARDs) with no differences between regions. Overall, the most used bDMARDs were adalimumab, certolizumab, tocilizumab and abatacept. At the time of the analysis 238 (36%) had discontinued bDMARDs treatment, 132 (47%) due to lack of response, being this the most frequent cause reported overall, with the highest rate in NR (62%, p <0.001). All NR patients have social security compared to 83% in CR and 79% in SR. Conclusion There are regional differences between patients with rheumatic diseases registered in Biobadamex. It was remarkable that all patients form NR had social security, which may impact in the access to treatment. There were differences in the treatments between regions. The data from this analysis may be useful to policy makers, pharmaceutical companies and physicians. Differences in size samples between regions could have influenced in the results, further analyses will be performed in the future including more patients. References [1]Peláez-Ballestas I et al. J Rheumatol 2011;86;3-8. [2]Chopra A et al. Best Pract Res Clin Rheumatol 2008;22:583-604. Disclosure of Interests VIJAYA RIVERA TERAN: None declared, David Vega-Morales: None declared, Sandra Sicsik: None declared, Fedra Irazoque-Palazuelos: None declared, Miguel A Saavedra: None declared, Julio Cesar Casasola: None declared, Sandra Carrilo: None declared, Angélica Peña: None declared, Angel Castillo Ortiz: None declared, Omar Eloy Muñoz-Monroy: None declared, Sergio Duran Barragan: None declared, Azucena Ramos: None declared, Luis Francisco Valdés Corona: None declared, Estefanía Torres Valdéz: None declared, Aleni Paz: None declared, ERICK ADRIAN ZAMORA-TEHOZOL: None declared, Alfonso Torres: None declared, Samara Mendieta: None declared, Daniel Xavier Xibille Friedmann: None declared, Francisco Guerrero: None declared, Natalia Santana: None declared, Miguel Vazquez: None declared, Claudia Zepeda: None declared, Melanea Rivera: None declared, Kitzia Alvarado: None declared, Deshire Alpizar-Rodriguez Consultant of: Scientific advisor for GSK, unrelated to this study., Employee of: Scientific advisor for GSK, unrelated to this study." @default.
• W4283707581 created "2022-06-30" @default.
• W4283707581 creator A5006303399 @default.
• W4283707581 creator A5007343612 @default.
• W4283707581 creator A5008700016 @default.
• W4283707581 creator A5011996585 @default.
• W4283707581 creator A5015195352 @default.
• W4283707581 creator A5019296716 @default.
• W4283707581 creator A5020923915 @default.
• W4283707581 creator A5022253258 @default.
• W4283707581 creator A5022724615 @default.
• W4283707581 creator A5026846211 @default.
• W4283707581 creator A5027761081 @default.
• W4283707581 creator A5041449263 @default.
• W4283707581 creator A5043098618 @default.
• W4283707581 creator A5043693935 @default.
• W4283707581 creator A5048637019 @default.
• W4283707581 creator A5057269219 @default.
• W4283707581 creator A5060109715 @default.
• W4283707581 creator A5063739063 @default.
• W4283707581 creator A5064301026 @default.
• W4283707581 creator A5065151379 @default.
• W4283707581 creator A5082594465 @default.
• W4283707581 creator A5084476790 @default.
• W4283707581 creator A5087561067 @default.
• W4283707581 creator A5088277662 @default.
• W4283707581 creator A5089134255 @default.
• W4283707581 creator A5089328061 @default.
• W4283707581 date "2022-05-23" @default.
• W4283707581 modified "2023-09-26" @default.
• W4283707581 title "POS1447 SOCIODEMOGRAPHIC, CLINICAL AND TREATMENT DIFFERENCES OF RHEUMATIC DISEASES IN THREE MEXICAN REGIONS." @default.
• W4283707581 doi "https://doi.org/10.1136/annrheumdis-2022-eular.4842" @default.
• W4283707581 hasPublicationYear "2022" @default.
• W4283707581 type Work @default.
• W4283707581 citedByCount "0" @default.
• W4283707581 crossrefType "journal-article" @default.
• W4283707581 hasAuthorship W4283707581A5006303399 @default.
• W4283707581 hasAuthorship W4283707581A5007343612 @default.
• W4283707581 hasAuthorship W4283707581A5008700016 @default.
• W4283707581 hasAuthorship W4283707581A5011996585 @default.
• W4283707581 hasAuthorship W4283707581A5015195352 @default.
• W4283707581 hasAuthorship W4283707581A5019296716 @default.
• W4283707581 hasAuthorship W4283707581A5020923915 @default.
• W4283707581 hasAuthorship W4283707581A5022253258 @default.
• W4283707581 hasAuthorship W4283707581A5022724615 @default.
• W4283707581 hasAuthorship W4283707581A5026846211 @default.
• W4283707581 hasAuthorship W4283707581A5027761081 @default.
• W4283707581 hasAuthorship W4283707581A5041449263 @default.
• W4283707581 hasAuthorship W4283707581A5043098618 @default.
• W4283707581 hasAuthorship W4283707581A5043693935 @default.
• W4283707581 hasAuthorship W4283707581A5048637019 @default.
• W4283707581 hasAuthorship W4283707581A5057269219 @default.
• W4283707581 hasAuthorship W4283707581A5060109715 @default.
• W4283707581 hasAuthorship W4283707581A5063739063 @default.
• W4283707581 hasAuthorship W4283707581A5064301026 @default.
• W4283707581 hasAuthorship W4283707581A5065151379 @default.
• W4283707581 hasAuthorship W4283707581A5082594465 @default.
• W4283707581 hasAuthorship W4283707581A5084476790 @default.
• W4283707581 hasAuthorship W4283707581A5087561067 @default.
• W4283707581 hasAuthorship W4283707581A5088277662 @default.
• W4283707581 hasAuthorship W4283707581A5089134255 @default.
• W4283707581 hasAuthorship W4283707581A5089328061 @default.
• W4283707581 hasBestOaLocation W42837075811 @default.
• W4283707581 hasConcept C126322002 @default.
• W4283707581 hasConcept C187212893 @default.
• W4283707581 hasConcept C2776260265 @default.
• W4283707581 hasConcept C2777077863 @default.
• W4283707581 hasConcept C2777402515 @default.
• W4283707581 hasConcept C2777575956 @default.
• W4283707581 hasConcept C71924100 @default.
• W4283707581 hasConceptScore W4283707581C126322002 @default.
• W4283707581 hasConceptScore W4283707581C187212893 @default.
• W4283707581 hasConceptScore W4283707581C2776260265 @default.
• W4283707581 hasConceptScore W4283707581C2777077863 @default.
• W4283707581 hasConceptScore W4283707581C2777402515 @default.
• W4283707581 hasConceptScore W4283707581C2777575956 @default.
• W4283707581 hasConceptScore W4283707581C71924100 @default.
• W4283707581 hasIssue "Suppl 1" @default.
• W4283707581 hasLocation W42837075811 @default.
• W4283707581 hasOpenAccess W4283707581 @default.
• W4283707581 hasPrimaryLocation W42837075811 @default.
• W4283707581 hasRelatedWork W145086642 @default.
• W4283707581 hasRelatedWork W1997363697 @default.
• W4283707581 hasRelatedWork W1997953917 @default.
• W4283707581 hasRelatedWork W2040982081 @default.
• W4283707581 hasRelatedWork W2068051896 @default.
• W4283707581 hasRelatedWork W2546290042 @default.
• W4283707581 hasRelatedWork W2614015912 @default.
• W4283707581 hasRelatedWork W2743764001 @default.
• W4283707581 hasRelatedWork W2785040221 @default.
• W4283707581 hasRelatedWork W4242931419 @default.
• W4283707581 hasVolume "81" @default.
• W4283707581 isParatext "false" @default.
• W4283707581 isRetracted "false" @default.
• W4283707581 workType "article" @default.